Press Releases

    • JUL 30 2019

    ONC201 In the Spotlight at Upcoming Symposium on Brain Cancer

    Philadelphia, PA (July 30, 2019) – Oncoceutics, Inc. announced that a series of presentations at the 2019 DIPG/DMG Symposium to be held August 2-3 in Sydney, Australia, will highlight ONC201 as a promising treatment for specific types of lethal brain cancer. These presentations are part of a session describing progress in new drug development for

    • JUL 23 2019

    Oncoceutics and the NCI PPTC Collaborate to Expand ONC201 Development in Pediatric Oncology

    Philadelphia, PA (July 23, 2019) – Oncoceutics, Inc., announced a collaboration with the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Consortium (PPTC) to enable tumor type selection for ONC201 clinical trials in pediatric oncology beyond diffuse midline gliomas. The PPTC program addresses key challenges associated with the development of new therapies for children with